
After two cancer diagnoses and major surgery, a liver cancer survivor shares why asking questions, exploring treatment options and advocating for your care matter.

After two cancer diagnoses and major surgery, a liver cancer survivor shares why asking questions, exploring treatment options and advocating for your care matter.

A custom mRNA vaccine is the first to succeed in a phase 3 trial. Learn how personalized cancer vaccines work and what to watch for at ESMO 2026.

A rising PSA after surgery or radiation can be frightening. Learn what biochemical recurrence means, which tests come next and your treatment options.

Three doctors dismissed Christine Kushner’s breast changes at 37. Trusting her gut and pushing for a mammogram helped save her life.

Six years after a B-cell ALL diagnosis at 21, William Yank shares how his view of therapy changed and why he is still working on his mental health.

A Phoenix man with metastatic castration-sensitive prostate cancer shares how back pain led to a PSA test and how his family helped him cope.

Five CURE bloggers living with breast cancer share what Breast Cancer Awareness Month can miss, from metastatic disease to men and mammogram limits.

A study of 39,184 people with solid tumors, published Oct. 8, 2026, found that about 1 in 6 had an inherited genetic change that increased their cancer risk. Testing only people under 50 would have missed 72% of those with these changes.

Updated NCCN guidelines for mantle cell lymphoma favor BTK inhibitor pills in first treatment and say people with no detectable lymphoma after treatment can skip a stem cell transplant.

From a personalized melanoma vaccine to new options for biliary, stomach, lung and endometrial cancers, here are 5 ESMO 2026 abstracts to watch.

In the phase 2 CO.28 trial, all 4 patients with tumor DNA in their blood after chemotherapy were recommended surgery, versus 38.1% of those without it.

California Gov. Gavin Newsom signed AB 1682 on Sept. 27, requiring large-group health plans to cover prescribed scalp cooling starting Jan. 1, 2027. Medi-Cal coverage is pending federal approval.

In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes.

In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.

In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.

Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.

Challenge yourself after cancer by building healthier habits, strengthening relationships, managing stress and embracing new experiences for a healthier life.

Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.

The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.

Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.

Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.

Tecentriq plus chemotherapy lowered the risk of cancer returning or death by 50% versus chemotherapy alone in patients with stage 3 dMMR colon cancer.

In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.

In a Johns Hopkins study, 64% of African American patients with myeloma received bone-modifying drugs in their first year, compared with 77% of White patients.

ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.

The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.

Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.

In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.